Business
embecta Completes Acquisition of Owen Mumford Holdings Limited
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies. On March 19, 2026, the two companies announced a definitive agreement for embecta to acquire Owen Mumford for an upfront ca
About this update from Embecta Corp.
[{"type":"image","alt":"Embecta Corp.","displaySize":"","headline":null,"caption":"Embecta Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/88b89c67eb25aa734a2e45950012ee2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0KtNeRWRAusSopswNglrzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/88b89c67eb25aa734a2e45950012ee2b","width":300,"height":150},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0KtNeRWRAusSopswNglrzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/88b89c67eb25aa734a2e45950012ee2b","width":300,"height":150}},"lazy":false},{"type":"text","content":"PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies.","length":376,"tagName":"p"},{"type":"text","content":"On March 19, 2026, the two companies announced a definitive agreement for embecta to acquire Owen Mumford for an upfront cash payment of £100 million and up to an additional £50 million in performance-based payments based on net sales of the Aidaptus® next generation auto-injector platform in the three-year period following the closing.","length":343,"tagName":"p"},{"type":"text","content":"The transaction accelerates embecta’s strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets. It provides embecta a differentiated drug-delivery platform designed to support pharmaceutical partners across multiple therapeutic areas and a strong underlying intellectual property portfolio, including the next-generation Aidaptus® auto-injector platform. It further adds a product portfolio of chronic care devices and leverages core manufacturing strengths in high volume medical products by combining Owen Mumford’s device design, molding and assembly capabilities in drug-delivery systems with embecta’s global commerci...